Publications by authors named "G W Waterer"
Respiratory syncytial virus pulmonary infections in adults - disease burden and prevention.
Curr Opin Pulm Med
December 2024
Purpose Of Review: We highlight the evolving understanding of the burden of respiratory syncytial virus (RSV) in older adults and recent data on the three new vaccines.
Recent Findings: As well as a greater recognition of the amount of RSV infection in adults, and especially over 60 years of age, there has been a significant amount of study detailing the postacute burden including excess cardiovascular disease and loss of physical and cognitive functioning. Three new RSV vaccines now have published data for two seasons, and while direct comparison is not possible due to differences in the timing, methodology and populations studies, all show good efficacy with no serious side effects of concern.
Objective: The timely identification of deterioration on general wards is crucial to patient care with each hour of delay independently associated with increased risk of death. The introduction of continuous monitoring of patient vital signs on general wards, currently not standard care, may improve patient outcomes. Our aim was to investigate whether patients on general wards receiving continuous vital signs monitoring have better outcomes than patients receiving usual care.
View Article and Find Full Text PDFArticle Synopsis
- Fungal lung disease includes various infections caused by fungi, particularly from the Aspergillus species, leading to conditions like allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis, influenced by the patient's immune response and the type of fungi.
- The diagnosis of these diseases is complicated by geographic and environmental factors as well as coexisting health issues, with new techniques developing but still facing challenges in speed and accuracy, especially in less developed areas.
- Treatments mainly use antifungal drugs, but drug resistance is becoming a significant problem; however, new antifungal medications and better understanding of the lung mycobiome could pave the way for improved diagnosis and therapy.